Ixinity Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Ixinity market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historic period can be attributed to factors such as the rising prevalence of hemophilia, increased investments in biotechnology, regulatory approvals, advancements in treatment modalities, and enhanced treatment efficacy.

Growth during the forecast period is expected to be driven by the increasing incidence of hemophilia, government funding and initiatives, a shift towards homecare solutions, regulatory approvals for new treatments, and supportive government policies. Key trends anticipated include improvements in manufacturing processes, regulatory challenges and discounts, the adoption of extended half-life factors, a heightened focus on gene therapy, and geographic market expansion.

The growing prevalence of hemophilia is expected to drive the expansion of the ixinity market in the coming years. Hemophilia is an inherited bleeding disorder where the blood does not clot properly, causing excessive bleeding either from injuries or spontaneously, which often requires medical intervention. The increasing number of hemophilia cases is attributed to genetic factors, greater awareness of acquired forms, and improved diagnostic techniques that allow for the detection of previously undiagnosed individuals. Ixinity is used in the treatment of hemophilia B to prevent and control bleeding episodes. It is a recombinant factor IX therapy that helps manage clotting deficiencies in individuals with hemophilia B. For example, in October 2023, the World Federation of Hemophilia, a Canada-based non-profit organization, estimated the prevalence of hemophilia to be around 17.1 per 100,000 males for hemophilia A and 3.8 per 100,000 for hemophilia B, with severe cases being rarer at 6 and 1.1 per 100,000, respectively. This results in approximately 830,895 people globally, including 282,266 with severe forms and over 257,146 diagnosed cases of hemophilia, including 208,957 for hemophilia A and 42,203 for hemophilia B, along with more than 100,000 cases of von Willebrand disease. Thus, the rising incidence of hemophilia is fueling the growth of the ixinity market.

The expanding aging population is expected to boost the growth of the ixinity market in the future. The aging population refers to the increasing share of elderly individuals within a population, driven by declining birth rates and longer life expectancy, which puts pressure on healthcare and social systems. As healthcare advancements increase life expectancy and lower birth rates reduce the proportion of younger individuals, the number of older people continues to rise. Ixinity benefits older individuals with hemophilia B by managing bleeding risks related to age-associated health issues, ensuring stable clotting factor IX levels. For example, according to statistics from the Population Reference Bureau (PRB), a US-based non-profit organization, the number of Americans aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. Their share of the total population is expected to rise from 17% to 23%. Therefore, the growing aging population is driving the growth of the ixinity market.

In March 2023, XOMA Corporation, a US-based biotechnology company, acquired the commercial payment and a portion of the milestone rights to IXINITY from Aptevo Therapeutics for an undisclosed amount. This acquisition aligns with XOMA's strategy to generate consistent cash flow and supports its objective of accelerating royalty aggregation. Aptevo Therapeutics Inc. is a US-based clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer treatment.

The key company operating in the ixinity market is Medexus Pharma Inc.

North America was the largest region in the ixinity market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ixinity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ixinity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ixinity is a recombinant form of clotting factor IX used to manage hemophilia B, a hereditary bleeding disorder. It is designed to replace the missing or insufficient factor IX in patients, helping to prevent and control bleeding. Manufactured through advanced biotechnology, Ixinity ensures a high degree of purity and effectiveness. The medication is typically administered via intravenous infusion and offers a long-acting solution, reducing the need for frequent infusions to maintain factor IX levels.

The primary indication of ixinity are routine prophylaxis, on-demand treatment, and perioperative management. Routine prophylaxis involves regularly scheduled treatments to prevent bleeding episodes in individuals with hemophilia. The patient demographics include pediatric patients, adult patients, and high-risk groups, and various end users are hospitals, clinics, hemophilia treatment centers, and home care settings.

The ixinity market research report is one of a series of new reports that provides ixinity market statistics, including ixinity industry global market size, regional shares, competitors with a ixinity market share, detailed ixinity market segments, market trends and opportunities, and any further data you may need to thrive in the ixinity industry. This ixinity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Ixinity market consists of sales of Ixinity (recombinant coagulation factor IX). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.